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INTRODUCTION
Knee osteoarthritis (KOA) is typically a slowly progressive disorder. However, accelerated KOA (AKOA) is a subset of KOA that is characterized by a rapid onset and progression of disease within 4 years (from preradiographic disease to advancedstage disease) and often in as little as 12 months (1-3). Adults with AKOA report greater pain and functional limitations up to 3 years prior to the onset of radiographic disease compared with those with a more common, gradual onset of KOA (typical KOA) (2, 4) . Additionally, individuals who developed AKOA were ~25 times more likely to receive a knee replacement than those who developed incident typical KOA (5) . Given that adults with AKOA experience more severe and early symptoms, they may be more likely to seek other surgical or pharmacological interventions as treatment options, even prior to the onset of disease.
Unfortunately, it remains unclear how adults who develop AKOA use pharmacological treatments (eg, over the counter or prescription nonsteroidal anti-inflammatory drugs [NSAID], intraarticular injections) or arthroscopic knee surgery before, during, and after disease onset compared with those who develop typical KOA or no KOA. Because adults with AKOA report greater pain and dysfunction even prior to the onset of disease, we hypothesized that adults with AKOA were more likely to receive a pharmacological treatment or arthroscopic knee surgery than those who develop typical KOA or no KOA, even prior to disease onset. Therefore, our primary purpose was to determine if those with incident AKOA were more likely to receive pharmacological or surgical treatment than those with incident typical KOA or no KOA. Secondarily, we sought to determine if individuals who developed AKOA received more pharmacological or surgical treatments prior to the onset of disease than their peers who developed typical KOA.
METHODS
We conducted a nested cohort study using data from baseline and the first 8 years of the Osteoarthritis Initiative (OAI). The OAI is a multicenter cohort study of 4796 adults with or at risk for symptomatic KOA. Staff at four clinical sites (Memorial Hospital of Rhode Island, The Ohio State University, University of Maryland and Johns Hopkins University, and the University of Pittsburgh) recruited participants between 2004 and 2006. OAI data, images, and protocols are publicly available (6) . Institutional review boards at all OAI clinical sites and coordinating center (University of California, San Francisco) approved the study. The OAI has been approved and the study protocol is in compliance with the ethical guidelines of the 1975 Declaration of Helsinki. Institutional review boards at each OAI clinical site and the OAI coordinating center (University of California, San Francisco) approved the OAI study. All participants provided informed consent prior to participation.
For our primary analysis, we considered any pharmacological or surgical treatment option during the first 8 years of the OAI, regardless of timing of disease onset. We performed one secondary analysis by examining the pharmacological or surgical treatment options prior to disease onset among those with incident AKOA or typical KOA.
Participants. For our primary analysis, we included participants with no radiographic KOA (Kellgren-Lawrence [KL] less than 2) and no knee replacement at baseline (n = 1935) to assess whether adults who developed AKOA received pharmacological or surgical treatment more than those who developed typical KOA or remained with no KOA. We classified three groups using KL grades from the first 8 years of the OAI: 1) AKOA: at least one knee progressed to advanced-stage KOA (KL 3 or 4) in 4 years or less, 2) typical KOA: at least one knee with any increase in KL grade (excluding those with AKOA), and 3) No KOA: no change in KL grade by 8 years (3, 5) .
Index Visit. For individuals who developed accelerated or typical KOA, the index visit was defined as the visit when a person met the definition for accelerated or typical KOA (12-, 24-, 36-, or 48-, 72-, or 96-month OAI visit).
Index Knee. For analyses with arthroscopic knee surgery or injections, the index knee was defined as the first knee to develop AKOA or typical KOA. For individuals with no KOA, we considered surgery or injections to either knee. Knee Radiographs. Bilateral weight-bearing, fixed-flexion posteroanterior knee radiographs were obtained at baseline and the first four annual follow-up visits as well as at the 6-and 8year follow-up visits. Blinded central readers recorded KL grades (0 to 4). The interrater agreement for the KL grades was good (weighted kappa = 0.70-0.80) (6) . For baseline and the first four annual readings, we primarily used KL readings in the OAI read project 15 (files: kXR_SQ_BU##_SAS [versions 0.8, 1.8, 3.7, 5.7, 6.5]). Because the 6-and 8-year follow-up images were read separately from the initial readings (read projects: 37/42; files: kXR_ SQ_BU##_SAS [versions 8.2 and 10.2]), we used 13 criteria to harmonize KL readings across read projects (see Supplementary Material for criteria).
Self-Reported Arthroscopic Knee Surgery. Arthroscopic knee surgery was self-reported at each follow-up visit in response to a question for the right and left knee: "Since your last annual visit to the OAI clinic, did you have arthroscopy (where they put a scope) in your right knee?". A similar question was asked for the left knee. We defined arthroscopic knee surgery as an affirmative response to an arthroscopy for the index knee during the observation period.
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Self-Reported Pharmacological Treatment. NSAIDS and injections. At baseline and each follow-up visit, participants reported the use of nonprescription NSAIDs or knee injection (eg, hyaluronic acid [HA], intra-articular corticosteroid [IACS]). For nonprescription NSAID use, study staff asked: "During the past 30 days, have you used any of the following medications for joint pain or arthritis on most days? By most days, we mean more than half the days of the month….Non-steroidal anti-inflammatory drugs, also called NSAIDs, that you can get without a prescription, such as Aspirin, Ibuprofen (Advil, Nuprin, Motrin), or Naproxen (Aleve)?" They then checked: "yes," "no," "don't know," or "refused." (6) For knee injections, study staff asked at each follow-up visit: "During the past 6 months, have you had any injections in either of your knees for treatment of arthritis?" If the participant responded "yes", then they were asked two follow-up questions: 1) "During the past 6 months, have you had an injection of hyaluronic acid (ie, HA; Synvisic or Hyalgan) in either knee of your knees for treatment of your arthritis? These injections are given in a series of 3 to 5 weekly injections" and 2) "During the past 6 months, have you had an injection of steroids (cortisone, corticosteroids) in either of your knees for treatment of your arthritis?" If the participant responded "yes" to either question, then they were asked "In which knee?" and the participant could reply: "right", "left", "both knees," or "don't know".
Nutraceuticals. At baseline and each follow-up visit, participants recorded the use of nutraceuticals (ie, chondroitin sulfate, glucosamine). Study staff asked: "During the past 6 months, did you use the following health supplements for joint pain or arthritis?" Chondroitin sulfate and glucosamine were the most common among users in the OAI and were combined because of the small percentage of users taking only one. For each chondroitin sulfate and glucosamine, they then checked: "yes," "no," "don't know," "or "refused."
Medication Inventory Form-Based Pharmacological Treatment. To assess use of prescription NSAIDs (eg, ibuprofen, naproxen), narcotics (eg, hydrocodone, codeine), and other analgesics (eg, acetaminophen, celecoxib, aspirin), we used the publicly available OAI Medication Inventory Forms, which have been described in detail elsewhere (6, 7) . At each visit, participants were advised to bring all prescription medications used in the 30 days prior to the visit. An examiner recorded all the prescription medications. In the medication inventory form data files, the medications are coded based on the Iowa Drug Information Service (IDIS) database developed at the University of Iowa (8, 9) . We used OAI-provided indicator variables that noted when a person brought in a relevant class of medication. Specifically, we considered prescription NSAIDs (IDIS number: 28080400-28080540), prescription narcotics (IDIS number: 28080800-28080898, 48000063, 48000071, 48000072), and other prescription analgesics (IDIS number: 28081200-28081320). We also included in our analyses an overall prescription analgesic category that grouped together the prescription NSAIDs, narcotics, and other analgesics.
Other Clinical Variables. We extracted participant characteristics from the public OAI data files: age, sex, and body mass index (BMI) (Files: enrollees, v.23; allclinical00, v.0.2.2). All variables were collected based on standardized procedures, which are defined in the OAI protocols and available on the OAI website (6) .
Statistical Analyses. After calculating basic descriptive statistics for the groups, we conducted a series of Chisquare tests to determine if use of pharmacological treatment or arthroscopic knee surgery differed among the three groups. When we conducted our secondary analysis, we performed Chi-square tests to determine if use of pharmacological treatment or arthroscopic knee surgery differed between adults who developed AKOA and typical KOA prior to the onset of disease (prior to index visit). For all analyses, we considered a P value less than 0.006 to be statistically significant (for eight comparisons). We performed all analyses in SAS Enterprise Guide 7.15.
RESULTS
Among 1935 participants without radiographic KOA at OAI baseline, we had sufficient longitudinal KL data to classify 1347 participants (69.6%). We identified 92 individuals with AKOA (63% female, 60.9 ± 8.8 years, BMI: 29.3 ± 4.8 kg/m 2 ), 380 with typical KOA (67% female, 58.7 ± 8.4 years, BMI: 27.8 ± 4.5 kg/m 2 ), and 875 with no KOA (52% female, 58.4 ± 8.6 years, BMI: 26.8 ± 4.4 kg/m 2 ). The most commonly used analgesic ingredients taken within the AKOA group were celecoxib, acetaminophen, and oxycodone. The typical KOA group used mainly naproxen, ibuprofen, and acetaminophen. Among those with no KOA, acetaminophen, celecoxib, and hydrocodone were the most commonly used analgesics.
Overall, those with AKOA were more likely to undergo an arthroscopic knee surgery (AKOA: 32% versus typical KOA: 8% or no KOA: 3%), receive HA injections (10% versus 4% or 1%) or IACS injections (30% versus 7% or 4%), or take nonprescription NSAIDs (65% versus 48% or 46%) or prescription analgesics (61% versus 43% or 41%), than those with typical KOA or no KOA, respectively (Table 1) . Adults with AKOA were slightly more likely to take nutraceuticals than those with typical KOA or no KOA (68% versus 52% or 49%).
Prior to the index visit, those who developed AKOA were more likely to use other prescription analgesics (eg, acetaminophen, celecoxib, aspirin: 7% versus 1%) than those who went on to develop typical KOA, as well as receive an arthroscopic knee surgery (11% versus 4%; Table 2 ). We observed no other differences prior to disease onset.
DISCUSSION
Despite all participants starting with no radiographic KOA at baseline, adults that developed AKOA were more likely to receive pharmacological treatment or arthroscopic knee surgery over the subsequent 8 years than those with typical KOA or no KOA. Contrary to our hypothesis, differences in treatment use were typically not as apparent prior to disease onset, even though individuals with AKOA present with more severe symptoms prior to disease onset (2) . This indicates that those with AKOA utilized treatment options and health care resources far more often than adults who developed typical KOA, likely because they quickly developed advanced-staged disease. Overall, adults with AKOA commonly received more treatments than their peers after disease onset, but not prior to disease onset. Previously, we observed that in the year before radiographic onset, individuals with AKOA experienced greater pain and dysfunction than adults who developed typical KOA (4). Although we observed no differences in most therapeutic options between groups prior to the onset of disease, prescription analgesic use was common in adults who developed typical KOA (30%) and AKOA (38%). This may support previous research showing that incident KOA, in general, is preceded by joint pain that may be sufficient enough to cause people to seek analgesic relief from a physician (4, 10, 11) . The presence of prodromal symptoms and frequent use of prescription analgesics reinforce suggestions that researchers and clinicians need to develop and deploy more comprehensive treatment strategies that address the underlying risk factors and etiology rather than palliative care prior to disease onset.
Interestingly, individuals who developed AKOA were more likely to receive arthroscopic knee surgery, even prior to disease onset, compared with their peers, which may contribute to greater cost of health care for people who develop AKOA. The high rate of arthroscopic knee surgery may be related to knee injuries, especially injuries causing a destabilizing meniscal tear, that are a risk factor for AKOA (1, 12, 13) . It may be prudent to more frequently examine patients during the first year or two after arthroscopic knee surgery for signs of AKOA.
A person with AKOA is more likely to receive a knee replacement than someone who develops typical KOA (5) . This and the more frequent receipt of arthroscopic knee surgery reiterates previous findings that AKOA is a clinically significant and severe subset of KOA that increases the likelihood of seeking out surgical treatment options (2) (3) (4) (5) . Adults with AKOA may be an important patient population that is understudied in current clinical research and a particularly appealing population for early disease-modifying interventions that will slow, halt, or reverse the onset of radiographic KOA.
Although this study is an important step in characterizing the pharmacological and surgical treatments among adults with AKOA, we acknowledge there are limitations. First, it is unclear who provided the treatments and why the individual was treated with certain medications or received an arthroscopic knee surgery. Although this may lessen our ability to infer causation, we believe this indicates that people with AKOA are more likely to receive pharmacological or surgical treatment regardless of cause. Additionally, the OAI is not a population-based study and relies on self-reported surgery, injections, and nonprescription NSAID use. Despite this, the OAI provides a unique opportunity to explore how adults who develop AKOA, or other subsets of OA, may manage their joint symptoms. It also provided valuable insight into the use of pharmacological options prior to the onset of KOA.
Despite starting without radiographic KOA, adults with AKOA received more pharmacological or surgical treatments over 8 years than those who develop typical KOA or no KOA. Adults with AKOA are an important patient population that is understudied in clinical research despite their use of greater health care resources.
Contrary to our hypothesis, differences between AKOA and typical KOA in treatment use were less apparent prior to disease onset, except for arthroscopic knee surgery. It may be beneficial to frequently evaluate patients after arthroscopic knee surgery for signs of possible AKOA. Finally, prior to disease onset almost 1 in 3 people with incident KOA used prescription analgesics, which supports calls for researchers and clinicians to develop and deploy more comprehensive treatment strategies that address the underlying risk factors and etiology prior to disease onset.
